Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery Jan 02 | 2024Holiday Hangover: FDA Issues Dasiglucagon CRL for CHI; Cytokinetics Ph3 Aficamten Results; NeuroBo Submits Obesity IND; New O5 Algorithm Trial Observed; Tirzepatide in T1DM Trial; Novo Warns Against Counterfeit Ozempic in US; Glucotrack Preclinical Implantable CGM DataPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Insulin Delivery, Other Dec 21 | 2023Lilly Partners for Obesity Drug Discovery; Embecta GLP-1RA CommentaryPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other Dec 18 | 2023Structure Tx Oral GLP-1RA Ph2a Results; Akero Doses First Patients in EFX Ph3 ProgramPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other Dec 15 | 2023Novo Buys Alkermes Manufacturing Facility for Oral Assets; Fractyl Announces New Revita Analysis; AZ Initiates Ph2 Oral PCSK9i Study in Dyslipidemia; Nexletol/Nexlizet Label UpdatesPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Dec 13 | 2023Alnylam 2023 Pipeline Updates; Pfizer Full-Year 2024 Guidance Call; Zepbound Available Through Ro Body Program; Novo Challenges IRA’s Constitutional Legitimacy; Tandem Source Full Launch in USPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Other, SGLT2i Dec 11 | 2023SURMOUNT-4 Results Published in JAMA; December CHMP Agenda; Fractyl Health Presents GLP-1RA PGTx Findings at WCIRDC 2023Purchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Other Dec 08 | 2023Sanofi 2023 Investor Day Pipeline Updates; Akero Initiates Ph3 EFX MASH Program; Biomea Presents Data at WCIRDC 2023; Matt Rainville Joins TandemPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Glucose Monitoring, Insulin Delivery, SGLT2i Dec 06 | 2023Medtronic Terminates EOFlow Acquistion; t:slim X2 Now Available with Dexcom G7 Integration; Indoco Receives Tentative Approval for Generic InvokanaPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other Dec 05 | 2023Zealand 2023 Investor Day Obesity Pipeline Updates; Zepbound Now Available; Inventiva Receives DMC Approval to Continue Ph3 MASH Trial; Ascensia Participates in Film Series for Eversense CGMPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other Dec 04 | 2023Roche to Acquire Carmot; 89bio Ph3 MASH ProgramPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA Dec 01 | 2023Pfizer Loses and Altimmune Wins with New Ph2 Obesity DataPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other Nov 30 | 2023Arrowhead CY Q3 ’23 (FY Q4 ’23) Earnings; Zealand Appoints Enrique Conterno and Elaine Sullivan as Board ObserversPurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Insulin Delivery Nov 29 | 2023SAB Initiates Ph1 T1DM study; Lilly Continues Verve Investment; Arecor Expands Collaboration with Lilly; Avidity Expands CV Partnership with BMSPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, SGLT2i Nov 28 | 2023Novartis 2023 Investor Day Pipeline Updates; New Lilly Obesity AssetPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other Nov 28 | 2023Novo Expands Production Facilities in France; Novo to Reduce Production of Victoza for Ozempic Supply; Mounjaro vs. Ozempic in Real-World Study; Kaleido Launches AID System; Biodexa Acquires T1DM Asset; 89bio Long-term MASH Data; Dario Contracts for Cardiometabolic SolutionPurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Glucose Monitoring, Insulin Delivery, Other Nov 21 | 2023Medtronic CY Q3 ’23 (FY Q2 ’24) Earnings; Lilly to Build Production Plant in Germany; Lilly Initiates Ph1 T2DM Study; Carmot Files for IPOPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA Nov 21 | 2023Zepbound (tirzepatide) Label and Website AnalysisPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery Nov 15 | 2023Novo Initiates Ph2 Cagrisema Trial in CKD and T2DM; Carmot Initiates Ph2 GLP-1/GIP RA Study in Obesity and T1DM; OptumRx Lowers Insulin Costs; Beta Bionics Gains Coverage for iLet Bionic Pancreas; Mark Estes Joins Biolinq; Belgium and Britain Ban Ozempic for Weight LossPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other Nov 14 | 2023Novo H2H Cagrisema vs. Tirzepatide Trial; Terns and Nemaura Q3 ’23 Earnings; Viking Ph2b MASH Data at AASLD; SAB Therapeutics Raises $67.1M for T1DM Treatment; Dexcom Launches #SeeDiabetes CampaignPurchase Blast
$599
Posted in: Other, SGLT2i Nov 13 | 2023AHA 2023: Roche/Alnylam, Amgen, Amarin, Esperion, and Lexicon Present New Data; Cleerly Partner Participation in TRANSFORM HF TrialPurchase Blast